Disposition of 2′, 3′-dideoxyadenosine and 2′, 3′-dideoxyinosine in mice
- 1 July 1989
- journal article
- Published by Springer Nature in Investigational New Drugs
- Vol. 7 (2-3) , 139-146
- https://doi.org/10.1007/bf00170850
Abstract
Mice were dosed with [3H]2′,3′-dideoxyadenosine ([3H]ddA) in three procedures: intravenously, intraperitoneally, and interperitoneally following a dose of 2′ -deoxycoformycin (dCF). For mice dosed intravenously, the content of radioactivity in plasma and tissue samples were essentially constant after 30 min. Of the radioactivity in plasma and brain samples collected between 30 min and 24 hr, more than 94% was present as 3H2O, indicating that most of the tritium from [3H]ddA had exchanged with water. No intact ddA was detected, and the deamination product, 2′,3′ -dideoxyinosine (ddI), was present only transiently. In the urine, the major radioactive material was [3H]ddI. Also detected were 3H2O and small amounts of [3H]hypoxanthine and [3H]ddA. Following intraperitoneal doses to mice, levels of radioactivity in plasma, liver, and kidney increased to a maximum by 15–30 min after dosing but dropped to essentially constant levels thereafter, again indicating that the tritium had exchanged with water. At 5, 15, and 30 min after dosing, ddI was the major radioactive component in plasma. Only small amounts of ddA were present. When dCF was administered 24 hr prior to intraperitoneal [3H]ddA, levels of radioactivity in plasma, liver, and kidney reached a maximum at 30 to 60 min after dosing and decreased to essentially constant levels thereafter. The dCF transiently inhibited the deamination of ddA to ddI, since, in plasma, [3H]ddA was the main radioactive component at 5 and 15 min after dosing. Comparison of HPLC assays based on radioactivity detection and UV absorbance showed that they were equivalent for measuring ddA and ddI in samples derived from dosed mice. Therefore, exchange of tritium must have occurred at a metabolic step beyond ddI. For mice dosed intravenously and orally with unlabeled ddI, there was evidence of a saturated process. Nevertheless, for the high and low intravenous doses of ddI, the percent of dose excreted in the urine as unchanged drug was the same.Keywords
This publication has 7 references indexed in Scilit:
- Initial studies on the cellular pharmacology of 2',3'-dideoxyadenosine, an inhibitor of HTLV-III infectivityBiochemical Pharmacology, 1987
- Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro.Proceedings of the National Academy of Sciences, 1987
- Both 2′,3′-dideoxythymidine and its 2′,3′-unsaturated derivative (2′,3′-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitroBiochemical and Biophysical Research Communications, 1987
- Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.Proceedings of the National Academy of Sciences, 1986
- Human erythrocytic purine nucleoside phosphorylase: reaction with sugar-modified nucleoside substratesBiochemistry, 1980
- A novel adenosine and ara‐a deaminase inhibitor, (R)‐3‐(2‐deoxy‐β‐D‐erythro‐pentofuranosyl)‐3,6,7,8‐tetrahydroimidazo[4,5 ‐d] [1,3]diazepin‐8‐olJournal of Heterocyclic Chemistry, 1974
- Isotopic hydrogen exchange in purine, adenine, adenosine, and benzimidazoleJournal of the Chemical Society D: Chemical Communications, 1971